Peptide record

TPDB92619

Peptide 2a ACE inhibitors Anticancer Antihypertensive Bitter iDPPIV modified_plain modified
2 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92619
Peptide 2a
ACE inhibitors Anticancer Antihypertensive Bitter iDPPIV
Cardiometabolic peptides Cancer-related peptides Food sensory peptides
Peptipedia CancerPPD 2.0 AHTPDB Tastepeptides-Meta iDPPIV
modified_plain
Yes
A 2-aa modified multi-activity (ACE inhibitors, Anticancer, Antihypertensive, and other sources) peptide sequence curated from Peptipedia, CancerPPD 2.0, AHTPDB, and other sources, with an available 3D structural model.
N-terminal: 4-(methylsulfonyl)benzoic acid
Sequence
YE
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
2 reviewed residue count
Free Activity
L Activity
Linear Activity
4-(methylsulfonyl)benzoic acid Activity
Antiproliferative, Anticancer Activity
Synthetic Activity
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 16.0 ± 0.13 µM
Anticancer
16.0

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2017

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 31.1 ± 0.03 µM
Anticancer
31.1

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2017
Evidence 3 Activity

Activity

IC50
IC50 = 20.6 ± 0.03 µM
Anticancer
20.6

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2017